Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.

Acta medica Okayama - 1 Aug 2016

Osawa Masahiro, Ohashi Kadoaki, Kubo Toshio, Ichihara Eiki, Takata Saburo, Takigawa Nagio, Takata Minoru, Tanimoto Mitsune, Kiura Katsuyuki

Abstract excerpt

Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma

Share to ErbB Receptors

Share to Hyperplasia

Share to Piperidines

Share to Quinazolines

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 27549668
DOI: 10.18926/AMO/54499

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.PMID 27549668Read ↗

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.Semantic proximity Read ↗

Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model.Semantic proximity Read ↗

ErbB2 Transgenic Mice: A Tool for Investigation of the Immune Prevention and Treatment of Mammary CarcinomasSemantic proximity Read ↗

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.Semantic proximity Read ↗

Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter.Semantic proximity Read ↗

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.Semantic proximity Read ↗

Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.Semantic proximity Read ↗

Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.Semantic proximity Read ↗

Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.Semantic proximity Read ↗

PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide.Semantic proximity Read ↗

Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.Semantic proximity Read ↗

VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.